AFP5h
Vertex Announces FDA Approval of JOURNAVX™ (suzetrigine), a First-in-Class Treatment for Adults With Moderate-to-Severe Acute Pain
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has ...
Le Lézard7m
Axsome Therapeutics Hosts SYMBRAVO® FDA Approval Virtual Investor Event with Expert Thought Leader
Axsome Therapeutics, Inc. , a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, will host a virtual investor event and conference call today at ...
NOLA.com18h
Get Back in the Game: Managing Knee Pain with ZILRETTA®
For active New Orleanians, knee osteoarthritis (OA) pain can sideline even the most passionate participants. Whether it’s ...
Zevra Therapeutics to Present at the 21st Annual WORLDSymposium™
Zevra to receive a 2025 New Treatment Award for MIPLYFFA™ at the 21st Annual WORLDSymposiumEight abstracts discussing data and clinical ...
What RFK Jr. Gets Right on Big Pharma
We agree that direct-to-consumer prescription-drug advertisements need to be reformed.
Becker's Hospital Review19h
FDA warns GLP-1 compounder over safety rules
The FDA issued a warning letter to ProRx, a compounding facility in Exton, Penn., after an inspection raised serious concerns regarding the safety and compliance of its drug products. The facility, ...
Frito Lay's Classic Potato Chips: Recall raised to highest risk level by FDA. What to know
The Food and Drug Administration just raised the recall level of Lay’s Classic Potato Chips to the highest risk classification. Frito Lay issued a recall on Dec. 16 through the FDA for over 6,000 bags ...